MX2020006846A - Sistema de hospedero/vector optimizado para la produccion de vacunas subunitarias monovalentes y multivalentes protectoras con base en la levadura de kluyveromyces lactis. - Google Patents

Sistema de hospedero/vector optimizado para la produccion de vacunas subunitarias monovalentes y multivalentes protectoras con base en la levadura de kluyveromyces lactis.

Info

Publication number
MX2020006846A
MX2020006846A MX2020006846A MX2020006846A MX2020006846A MX 2020006846 A MX2020006846 A MX 2020006846A MX 2020006846 A MX2020006846 A MX 2020006846A MX 2020006846 A MX2020006846 A MX 2020006846A MX 2020006846 A MX2020006846 A MX 2020006846A
Authority
MX
Mexico
Prior art keywords
lactis
vaccines
yeast
multivalent
subunit
Prior art date
Application number
MX2020006846A
Other languages
English (en)
Inventor
Karin Breunig
Hans Caspar Hührlimann
Martina Behrens
Mandy Gebauer
Sven- Erik BEHRENS
Original Assignee
Verovaccines Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verovaccines Gmbh filed Critical Verovaccines Gmbh
Publication of MX2020006846A publication Critical patent/MX2020006846A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nutrition Science (AREA)

Abstract

La invención se refiere a levaduras de Kluyveromyces lactis recombinantes (K. lactis), las cuales son capaces de presentar una expresión altamente eficiente de una o más proteínas extrañas y son adecuadas para usarse como una vacuna para generar una respuesta inmunitaria protectora contra los patógenos. La invención proporciona en particular las cepas de K. lactis para la clonación dirigida de los ácidos nucleicos que codifican el antígeno extraño en el genoma de la levadura de la cepa de K. lactis, la cual se caracteriza porque la cepa de K. lactis tiene casetes de expresión integrados para los antígenos extraños como una alternativa o además del locus KILAC4 o el locus KIURA3-20 (KLLA0E2277 lg) y/o en el locus KIMET5-1 (KLLA0B03938g). La invención se refiere además a los vectores de expresión de integración y a los métodos para la producción de las cepas de K. lactis de la invención así como al uso de las mismas como vacunas.
MX2020006846A 2017-12-27 2018-12-19 Sistema de hospedero/vector optimizado para la produccion de vacunas subunitarias monovalentes y multivalentes protectoras con base en la levadura de kluyveromyces lactis. MX2020006846A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102017012109.5A DE102017012109A1 (de) 2017-12-27 2017-12-27 Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
PCT/DE2018/000379 WO2019129321A2 (de) 2017-12-27 2018-12-19 Optimiertes wirts-/vektorsystem zur erzeugung protektiver mono- und multivalenter subunit-vakzine auf basis der hefe kluyveromyces lactis

Publications (1)

Publication Number Publication Date
MX2020006846A true MX2020006846A (es) 2020-11-06

Family

ID=65817691

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020006846A MX2020006846A (es) 2017-12-27 2018-12-19 Sistema de hospedero/vector optimizado para la produccion de vacunas subunitarias monovalentes y multivalentes protectoras con base en la levadura de kluyveromyces lactis.

Country Status (12)

Country Link
US (2) US11905517B2 (es)
EP (1) EP3732293B1 (es)
JP (2) JP2021508496A (es)
KR (1) KR20200104367A (es)
CN (1) CN111801422B (es)
BR (1) BR112020013245A2 (es)
CA (1) CA3086598A1 (es)
DE (2) DE102017012109A1 (es)
EA (1) EA202091435A1 (es)
MX (1) MX2020006846A (es)
WO (1) WO2019129321A2 (es)
ZA (1) ZA202003553B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4001417A1 (en) * 2020-11-13 2022-05-25 serYmun Yeast GmbH Yeast platform for the production of vaccines

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US7083787B2 (en) 2000-11-15 2006-08-01 Globeimmune, Inc. Yeast-dendritic cell vaccines and uses thereof
EP1581174B1 (en) * 2002-12-16 2018-04-25 GlobeImmune, Inc. Yeast-based vaccines as immunotherapy
WO2006044923A2 (en) 2004-10-18 2006-04-27 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis c infection
JP5198290B2 (ja) 2006-02-02 2013-05-15 グローブイミューン，インコーポレイテッド 免疫反応を誘発する酵母ベースワクチン
DE102008057451A1 (de) 2008-11-14 2010-05-20 Martin-Luther-Universität Halle-Wittenberg Verfahren zur oralen Vakzinierung mittels rekombinanter Hefen
JP5759980B2 (ja) * 2009-04-17 2015-08-05 グローブイミューン，インコーポレイテッド 癌および感染症に対する免疫療法組成物の組み合わせ
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene

Also Published As

Publication number Publication date
EP3732293B1 (de) 2024-07-03
WO2019129321A2 (de) 2019-07-04
KR20200104367A (ko) 2020-09-03
EA202091435A1 (ru) 2020-08-28
WO2019129321A3 (de) 2019-09-12
EP3732293A2 (de) 2020-11-04
US20240102031A1 (en) 2024-03-28
CA3086598A1 (en) 2019-07-04
ZA202003553B (en) 2021-06-30
JP2021508496A (ja) 2021-03-11
CN111801422B (zh) 2024-06-14
CN111801422A (zh) 2020-10-20
DE112018006647A5 (de) 2020-10-01
US20210230612A1 (en) 2021-07-29
US11905517B2 (en) 2024-02-20
JP2023166412A (ja) 2023-11-21
DE102017012109A1 (de) 2019-06-27
BR112020013245A2 (pt) 2020-12-01

Similar Documents

Publication Publication Date Title
MX2017002791A (es) Vacuna contra filovirus de virus vaccinia ankara modificado (mva) recombinante.
WO2015142671A3 (en) Influenza virus vectors and uses therefor
MX346245B (es) Proteina de fusion que comprende el mutante crm197 no toxico de toxina de difteria.
MX2023006203A (es) Vacunas novedosas contra el virus de zika.
MX2016009189A (es) Vacuna terapeutica potenciadora de inmunidad para virus de papiloma humano (vph) y enfermedades relacionadas.
PH12015500308A1 (en) Hepatitis b virus core protein and surface antigen protein and vaccine comprising the same
SG10201901053TA (en) Novel tilapia virus and uses thereof
MX351643B (es) Antigeno ndv recombinante y usos del mismo.
WO2014009586A3 (es) Vectores para la transformacion de mycoplasma hyopneumoniae, cepas transformadas de m. hyopneumoniae, y uso correspondiente
NZ601609A (en) Vaccine vectors and methods of enhancing immune responses
WO2011156619A3 (en) Vaccine and methods to reduce campylobacter infection
ZA201707985B (en) Recombinant modified vaccinia virus ankara (mva) foot and mouth disease virus (fmdv) vaccine
WO2019006401A3 (en) LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF
PH12019500578A1 (en) New promoters
MX2020006846A (es) Sistema de hospedero/vector optimizado para la produccion de vacunas subunitarias monovalentes y multivalentes protectoras con base en la levadura de kluyveromyces lactis.
WO2012174455A3 (en) Group a streptococcus multivalent vaccine
WO2012138754A3 (en) Mycobacterial vaccine vectors and methods of using the same
WO2018102774A8 (en) Pneumococcal vaccine combining selected alpha helical domains and proline rich domains of pneumococcal surface protein a
WO2020065349A3 (en) Vaccines and methods
JP2015507472A5 (es)
EA202090628A1 (ru) Система экспрессии paramyxoviridae
WO2018066948A3 (ko) 다수의 에피토프로 구성된 재조합 항원 단백질 및 이의 제조방법
WO2008118936A3 (en) Method of elicting immune response with a modified mva viral hiv-1 vector
WO2011064437A3 (es) Vectores virales y procedimientos útiles en la preparación de gdnf
WO2005089101A3 (en) Non-pathogenic listeria vaccine vectors and methods of treatment therewith